Current participant inclusion criteria as of 27/01/2022: 1. Participant or their legal representative, is willing and able to give informed consent for participation in the study, and is willing to comply with all trial procedures 2. A positive test for SARS-CoV-2 infection within the past 14 days (patient reported PCR test or lateral flow test result), with symptoms consistent with COVID-19* 3. Symptoms must have started within the past 14 days and be ongoing 4. Participant is aged 18 or over These symptoms may include, but are not limited to: a high temperature, a new, continuous cough, loss or change to your sense of smell or taste, sore throat, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea and vomiting. Previous participant inclusion criteria as of 26/04/2021: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Suspected COVID-19 using the NHS syndromic definition, or symptoms consistent with COVID-19 (including, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea and vomiting) and with a positive test for SARS-CoV-2 infection within the past 14 days 4. Aged 65 years or over, aged 18-64 and is experiencing shortness of breath as part of COVID-19 illnesses, or aged 18-64 and has any of the following underlying health conditions: 4.1. Known weakened immune system due to a serious illness or medication (e.g. chemotherapy), 4.2. Known heart disease and/or a diagnosis of high blood pressure 4.3. Known chronic lung disease (e.g. asthma) 4.4. Known diabetes 4.5. Known mild hepatic impairment, 4.6. Known stroke or neurological problem, 4.7. Self-report obesity or body mass index =35 kg/m² Previous participant inclusion criteria as of 08/06/2020: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 14 days of inclusion OR a positive test for SARS-Co-V2 infection which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting,fever and cough, and they must have had them for fewer than 15 days. 4. Patients aged =50-64 years with any of the following listed comorbidities OR patients aged =65 years with or without comorbidity: 4.1. Known weakened immune system due to serious illness or medication (e.g. chemotherapy) 4.2. Known heart disease and/or hypertension 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem _____ Previous inclusion criteria: 1. Participant is wil

Current participant inclusion criteria as of 27/01/2022: 1. Participant or their legal representative, is willing and able to give informed consent for participation in the study, and is willing to comply with all trial procedures 2. A positive test for SARS-CoV-2 infection within the past 14 days (patient reported PCR test or lateral flow test result), with symptoms consistent with COVID-19* 3. Symptoms must have started within the past 14 days and be ongoing 4. Participant is aged 18 or over These symptoms may include, but are not limited to: a high temperature, a new, continuous cough, loss or change to your sense of smell or taste, sore throat, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea and vomiting. Previous participant inclusion criteria as of 26/04/2021: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Suspected COVID-19 using the NHS syndromic definition, or symptoms consistent with COVID-19 (including, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea and vomiting) and with a positive test for SARS-CoV-2 infection within the past 14 days 4. Aged 65 years or over, aged 18-64 and is experiencing shortness of breath as part of COVID-19 illnesses, or aged 18-64 and has any of the following underlying health conditions: 4.1. Known weakened immune system due to a serious illness or medication (e.g. chemotherapy), 4.2. Known heart disease and/or a diagnosis of high blood pressure 4.3. Known chronic lung disease (e.g. asthma) 4.4. Known diabetes 4.5. Known mild hepatic impairment, 4.6. Known stroke or neurological problem, 4.7. Self-report obesity or body mass index =35 kg/m² Previous participant inclusion criteria as of 08/06/2020: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 14 days of inclusion OR a positive test for SARS-Co-V2 infection which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting,fever and cough, and they must have had them for fewer than 15 days. 4. Patients aged =50-64 years with any of the following listed comorbidities OR patients aged =65 years with or without comorbidity: 4.1. Known weakened immune system due to serious illness or medication (e.g. chemotherapy) 4.2. Known heart disease and/or hypertension 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem _____ Previous inclusion criteria: 1. Participant is wil

Current participant inclusion criteria as of 26/04/2021: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Suspected COVID-19 using the NHS syndromic definition, or symptoms consistent with COVID-19 (including, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea and vomiting) and with a positive test for SARS-CoV-2 infection within the past 14 days 4. Aged 65 years or over, aged 18-64 and is experiencing shortness of breath as part of COVID-19 illnesses, or aged 18-64 and has any of the following underlying health conditions: 4.1. Known weakened immune system due to a serious illness or medication (e.g. chemotherapy), 4.2. Known heart disease and/or a diagnosis of high blood pressure 4.3. Known chronic lung disease (e.g. asthma) 4.4. Known diabetes 4.5. Known mild hepatic impairment, 4.6. Known stroke or neurological problem, 4.7. Self-report obesity or body mass index =35 kg/m² Previous participant inclusion criteria as of 08/06/2020: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 14 days of inclusion OR a positive test for SARS-Co-V2 infection which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting,fever and cough, and they must have had them for fewer than 15 days. 4. Patients aged =50-64 years with any of the following listed comorbidities OR patients aged =65 years with or without comorbidity: 4.1. Known weakened immune system due to serious illness or medication (e.g. chemotherapy) 4.2. Known heart disease and/or hypertension 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem _____ Previous inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 7 days of inclusion 4. Patients aged =65 with or without comorbidity, and patients aged =50 years with the following listed comorbidities: 4.1. Known weakened immune system due to serious illness or infection (e.g. chemotherapy) 4.2. Known heart disease 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem

Current participant inclusion criteria as of 26/04/2021: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Suspected COVID-19 using the NHS syndromic definition, or symptoms consistent with COVID-19 (including, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea and vomiting) and with a positive test for SARS-CoV-2 infection within the past 14 days 4. Aged 65 years or over, aged 18-64 and is experiencing shortness of breath as part of COVID-19 illnesses, or aged 18-64 and has any of the following underlying health conditions: 4.1. Known weakened immune system due to a serious illness or medication (e.g. chemotherapy), 4.2. Known heart disease and/or a diagnosis of high blood pressure 4.3. Known chronic lung disease (e.g. asthma) 4.4. Known diabetes 4.5. Known mild hepatic impairment, 4.6. Known stroke or neurological problem, 4.7. Self-report obesity or body mass index =35 kg/m² Previous participant inclusion criteria as of 08/06/2020: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 14 days of inclusion OR a positive test for SARS-Co-V2 infection which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting,fever and cough, and they must have had them for fewer than 15 days. 4. Patients aged =50-64 years with any of the following listed comorbidities OR patients aged =65 years with or without comorbidity: 4.1. Known weakened immune system due to serious illness or medication (e.g. chemotherapy) 4.2. Known heart disease and/or hypertension 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem _____ Previous inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 7 days of inclusion 4. Patients aged =65 with or without comorbidity, and patients aged =50 years with the following listed comorbidities: 4.1. Known weakened immune system due to serious illness or infection (e.g. chemotherapy) 4.2. Known heart disease 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem

Current inclusion criteria as of 08/06/2020: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 14 days of inclusion OR a positive test for SARS-Co-V2 infection which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting,fever and cough, and they must have had them for fewer than 15 days. 4. Patients aged =50-64 years with any of the following listed comorbidities OR patients aged =65 years with or without comorbidity: 4.1. Known weakened immune system due to serious illness or medication (e.g. chemotherapy) 4.2. Known heart disease and/or hypertension 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem _____ Previous inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 7 days of inclusion 4. Patients aged =65 with or without comorbidity, and patients aged =50 years with the following listed comorbidities: 4.1. Known weakened immune system due to serious illness or infection (e.g. chemotherapy) 4.2. Known heart disease 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem

Current inclusion criteria as of 08/06/2020: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 14 days of inclusion OR a positive test for SARS-Co-V2 infection which was taken fewer than 15 days ago, AND the participant is unwell with symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, diarrhoea, vomiting,fever and cough, and they must have had them for fewer than 15 days. 4. Patients aged =50-64 years with any of the following listed comorbidities OR patients aged =65 years with or without comorbidity: 4.1. Known weakened immune system due to serious illness or medication (e.g. chemotherapy) 4.2. Known heart disease and/or hypertension 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem _____ Previous inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study 2. Participant is willing to comply with all trial procedures 3. Onset of symptoms of possible COVID-19 in the community (continuous cough and/or high temperature) should be within 7 days of inclusion 4. Patients aged =65 with or without comorbidity, and patients aged =50 years with the following listed comorbidities: 4.1. Known weakened immune system due to serious illness or infection (e.g. chemotherapy) 4.2. Known heart disease 4.3. Known asthma or lung disease 4.4. Known diabetes not treated with insulin 4.5. Known mild hepatic impairment 4.6. Known stroke or neurological problem